The Global Health Innovation Technology Fund (GHIT) has recently funded an exciting two-year project for the development of a next-generation malaria vaccine. PATH will work with partners from Ehime University and Sumitomo Dainippon Pharma Co., Ltd on the preclinical development of the novel transmission-blocking vaccine candidate Pfs230D1+ formulated with the novel SA-1 adjuvant. This project builds on previous research conducted by Ehime University and PATH with a grant from the GHIT Fund.
The GHIT Fund has also recently funded a project to evaluate the capacity of CoPoP, a novel liposomal delivery platform to co-deliver Pfs230 and CSP, two lead malaria vaccine candidates, to block parasite transmission from humans to mosquitoes and vice versa.
PATH has been working with the GHIT Fund since 2013 on various preclinical studies to inform the development of a next-generation malaria vaccine. Malaria remains one of the most pressing global health problems. According to the World malaria report 2019, malaria caused over 400,000 deaths in 2018.